Viruses of the Bunya- and Togaviridae families: Potential as bioterrorism agents and means of control

Antiviral Research

Volumn 57, Issue 1-2, 2003, Pages 101-111

  Sidwell, Robert W ^a   Smee, Donald F ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Crimean Congo hemorrhagic fever virus; Hantaan virus; Hantavirus; Punta Toro virus; Rift Valley fever virus; Sandfly fever virus; Venezuelan equine encephalitis virus

Indexed keywords

ACETIC ACID DERIVATIVE; ALPHA INTERFERON; AMPLIGEN; BROPIRIMINE; DEZAGUANINE; IMMUNOFERON; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; INTERFERON INDUCING AGENT; INTERLEUKIN 2; ISATORIBINE; NUCLEOSIDE ANALOG; PIRAZOFURIN; PYRAN COPOLYMER; PYRIMIDINONE DERIVATIVE; RECOMBINANT ALPHA INTERFERON A; RIBAMIDINE; RIBAVIRIN; SELENAZOFURIN; TIAZOFURIN; VIRUS VACCINE; ZYMOSAN;

AEROSOL; BIOLOGICAL WARFARE; BUNYAVIRUS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG SENSITIVITY; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; EMERGENCY TREATMENT; EPIDEMIC; FATALITY; HANTAVIRUS; HEMORRHAGIC FEVER; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; NAIRO VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIFT VALLEY FEVER BUNYAVIRUS; RNA VIRUS INFECTION; TOGAVIRUS; TREATMENT FAILURE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS CULTURE; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS TRANSMISSION; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALIA; BUNYAVIRIDAE; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; EQUIDAE; HANTAAN VIRUS; HANTAVIRUS; PUNTA TORO VIRUS; RIFT VALLEY FEVER VIRUS; SANDFLY FEVER SICILIAN VIRUS; TOGAVIRIDAE; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS;

EID: 0037282175     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00203-6     Document Type: Article

References (133)

1. Aguilar M. Pathological changes in brain and other target organs of infant and weanling mice after infection with non-neuroadapted western equine encephalitis virus. Infect. Immun. 2:1970;533-542.
2. Al-Makib W., Lloyd G., El-Mekki A., Platt G., Beeson A., Southee T. Preliminary report on arbovirus-antibody prevalence among patients in Kuwait: evidence of Congo/Crimean virus infection. Trans. Soc. Trop. Med. Hyg. 78:1984;474-476.
3. Anderson G.W. Jr., Slayter M.V., Hall W., Peters C.J. Pathogenesis of a phleboviral infection (Punta Toro virus) in golden Syrian hamsters. Arch. Virol. 114:1990;203-212.
4. Anonymous, 1993. Update: Hantavirus Disease-United States. MMWR 42, 612-614.
5. Atkins G.J., Sheahan B.J., Mooney D.A. Pathogenicity of Semliki Forest virus for the rat central nervous system and primary rat neural cell cultures: possible implications for the pathogenesis of multiple sclerosis. Neuropathol. Appl. Neurobiol. 16:1990;57-68.
6. Avsic-Zupanc T., Xiao S.Y., Stojanovic R., Gligic A., van der Groen G., LeDuc J.W. Characterization of Dobrava virus: a hantavirus from Slovenia, Yugoslavia. J. Med. Virol. 38:1992;132-137.
7. Barnett, I., Suyemoto, 1961. Field studies on sandfly fever and Kala-azar in Pakistan, in Iran, and in Baltistan (little Tibet) Kashmir. Trans. NY Acad. Sci. 23, 609-617.
8. Ben-Nathan D., Maestroni G.J., Lustig S., Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch. Virol. 140:1995;223-230.
9. Bennett A.M., Lescott T., Phillpotts R.J. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus. Viral Immunol. 11:1998;109-117.
10. Bhagrath M., Sidwell R.W., Czako K., Seyda K., Anderson W., Bodor N., Brewster M.E. Improved delivery through biological membranes. 54. Synthesis, characterization and antiviral activity of a series of ribavirin chemical delivery systems: 5′ and carboxamide derivatives. Antivir. Chem. Chemother. 2:1991;265-286.
11. Bianchi T.I., Aviles G., Sabattini M.S. Biological characteristics of an enzootic subtype of western equine encephalomyelitis virus from Argentina. Acta Virol. 41:1997;13-20.
12. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. J. Am. Med. Assoc. 287:2002;2391-2405.
13. Bradish C.J., Allner K., Maber H.B. The virulence of original and derived strains of Semliki Forest virus for mice. J. Gen. Virol. 12:1971;141-160.
14. Brewster M., Sidwell R., Deyrup M., Bodor N. Brain-enhanced delivery of ribavirin through use of redox targeting. Recent Adv. Chemother. 1:1992;1342-1343.
15. Bronze M.S., Huycke M.M., Machado L.J., Voskuhl G.W., Greenfield R.A. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 323:2002;316-325.
16. Burney M.I., Ghafoor A., Saleen M., Webb P.A., Casals J. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean hemorrhagic fever-Congo virus in Pakistan, January 1976. Am. J. Trop. Med. Hyg. 29:1980;941-947.
17. Canonico P.G., Jahrling P.B., Pannier W.L. Antiviral efficacy of pyrazofurin against selected RNA viruses. Antiviral Res. 2:1982;331-337.
18. Casals J., Curnen E., Thomas L. Venezuelan equine encephalomyelitis in man. J. Exp. Med. 77:1943;521-530.
19. Casals J., Henderson B.E., Hoogstraad H., Johnson K.M., Shelakov A. A review of Soviet viral hemorrhagic fevers, 1969. J. Infect. Dis. 122:1970;437-453.
20. Causey O., Causey C., Maroja O. The isolation of arthropod-borne viruses, including members of two hitherto undescribed serological groups, in the Amazon region of Brazil. Am. J. Trop. Med. Hyg. 10:1961;227-249.
21. Chaparro J., Vega J., Terry W., Vera J.L., Barra B., Meyer R., Peters C.J., Khan A.S., Ksiazek T.G. Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. J. Hosp. Infect. 40:1998;281-285.
22. Charles P.C., Walters E., Margolis F., Johnston R.E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology. 208:1995;662-671.
23. Christopher G.W., Cieslak T.J., Pavlin J.A., Eitzen E.M. Biological warfare: a historical perspective. J. Am. Med. Assoc. 278:1997;412-417.
24. Daubney R., Hudson J., Garnham P. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. J. Path. Bact. 34:1931;545-579.
25. Davis N.L., Powell N., Greenwald G.F., Willis L.V., Johnson B.J., Smith J.F., Johnson R.E. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full length cDNA clone. Virology. 183:1991;20-31.
26. Deyrup M., Sidwell R.W., Little R., Druzgala P., Bodor N., Brewster M.E. Improved delivery through biological membranes. Synthesis and antiviral activity of a series of ribavirin chemical delivery systems: 2′ and 3′ derivatives. Antivir. Chem. Chemother. 2:1991;337-356.
27. Dremov D.P., Solyanik R.G., Miryutova T.L., Laptakova L.M. Attenuated variants of eastern equine encephalomyelitis virus: pathomorphological, immunofluorescence and virological studies of infection in Syrian hamsters. Acta Virol. 22:1978;139-145.
28. Duchin J.S., Koster F.T., Peters C.J., Simpson G.L., Tempest B., Zaki S.R., Ksiazek T.G., Rollin P.E., Nichol S., Umland E.T. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N. Engl. J. Med. 330:1994;949-955.
29. Earnest M.P., Goolishian H.A., Calverley J.R., Hayes R.O., Hill H.R. Neurologic, intellectual. Neurology. 21:1971;969-974.
30. El-Karamany R., Imam I., Farid A. Production of inactivated RVF vaccine. J. Egypt. Publ. Health Assoc. 56:1981;495-525.
31. Finley K., Longshore W., Palmer R. Western equine and St. Louis encephalitis: preliminary report of a clinical follow-up study in California. Neurology. 5:1955;223-235.
32. Fisher-Hoch S.P., Khan J.A., Rehman S., Mirza S., Khurshid M., McCormick J.B. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet. 346:1995;472-475.
33. Fothergill L., Dingle J., Farber S. Human encephalitis caused by the virus of the eastern variety of equine encephalomyelitis. N. Engl. J. Med. 219:1999;411-422.
34. Frank-Peterside N. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine - TSI-GSD 200. Afr. J. Med. Med. Sci. 29:2000;89-92.
35. Franz D.R., Jahrling P.B., Friedlander A.M., McClain D.J., Hoover D.L., Bryne W.R., Pavlin J.A., Christopher G.W., Eitzen E.M. Jr. Clinical recognition and management of patients exposed to biological warfare agents. J. Am. Med. Assoc. 278:1997;399-411.
36. Gleiser C., Gochenour W., Berge T. The comparative pathology of experimental Venezuelan equine encephalomyelitis infection in different animal hosts. J. Infect. Dis. 110:1962;80-97.
37. Gorelkin L., Jahrling P.B. Virus-initiated septic shock. Acute death of Venezuelan encephalitis virus-infected hamsters. Lab. Invest. 32:1975;78-85.
38. Griffin, D.E., 2001. Alphaviruses. In: Knipe, D.M., et al. (Eds.), Fields Virology. Lippincott Williams and Wilkins, Philadelphia, pp. 917-962.
39. Groen J., Gerding M., Koeman J.P., Roholl P.J., van Amerongen G., Jordans H.G., Niesters H.G., Osterhaus A.D. A macaque model for hantavirus infection. J. Infect. Dis. 172:1995;38-44.
40. Hammon W., Reeves W., Brookman B. Mosquitoes and encephalitis in the Yakima Valley, Washington. I. Arthropods tested and recovery of western equine and St. Louis viruses from Culex tarsalis Coquillett. J. Infect. Dis. 70:1942;263-266.
41. Hardy J.L., Presser S.B., Chiles R.E., Reeves W.C. Mouse and baby chicken virulence of enzootic strains of western equine encephalomyelitis virus from California. Am. J. Trop. Med. Hyg. 57:1997;240-244.
42. Henry E.M., Kini G.D., Larson S.B., Robins R.K., Alaghamandan H.A., Smee D.F. Synthesis and broad-spectrum antiviral activity of 7,8-dihydro-7-methyl-8-thioxoguanosine. J. Med. Chem. 33:1990;2127-2130.
43. Hertig, M., Sabin, A., 1964. Sandfly fever (pappataci, Phlebotomus, 3-day fever). In: Hoff, E. (Ed.), Preventive Medicine in World War II, vol. 7. Communicable Diseases. Office of the Surgeon General, US Department of the Army, Washington, DC, pp. 109-174.
44. Hitchcock G., Porterfield J. The production of interferon in brains of mice infected with an arthropod-borne virus. Virology. 13:1961;363-365.
45. Hoogstraal H. The epidemiology of tick-borne Crimean/Congo hemorrhagic fever in Asia, Europe, and Africa. J. Med. Entomol. 15:1979;307-417.
46. Hooper J., Li D. Vaccines against hantaviruses. Curr. Top. Microbiol. Immunol. 256:2001;171-191.
47. Hooper J.W., Larsen T., Custer D.M., Schmaljohn C.S. A lethal disease model for hantavirus pulmonary syndrome. Virology. 289:2001;6-14.
48. Huffman J.H., Sidwell R.W., Robins R.K., Revankar G.R., Pifat D.Y. In vitro and in vivo phlebovirus inhibition by nucleosides related to ribavirin. Nucleotides Nucleosides. 8:1989;1159-1160.
49. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4):1989;S750-S761.
50. Huggins, J.W., Jahrling, P., Kende, M., Canonico, P., 1984. Efficacy of ribavirin against virulent RNA virus infections. In: Smith, R., et al. (Eds.), Clinical Applications of Ribavirin. Academic Press, New York, pp. 49-64.
51. Huggins J.W., Kim G.R., Brand O.M., McKee K.T. Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153:1986;489-497.
52. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., LeDuc J.W., Zheng Z.M., Meegan J.M., Wang Q.N., Oland D.D., Gui X.E., Gibbs P.H., Yuan G.H., Zhang T.M. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1991;1119-1127.
53. Huxsoll D.L., Patrick W.C., Parrott C.D. Veterinary services in biological disasters. J. Am. Vet. Med. Assoc. 190:1987;714-722.
54. Jackson A.C., Rossiter J.P. Apoptotic cell death is an important cause of neuronal injury in experimental Venezuelan equine encephalitis virus infection of mice. Acta Neuropathol. 93:1997;349-453.
55. Jahrling P.B. Virulence heterogeneity of a predominantly avirulent western equine encephalitis virus population. J. Gen. Virol. 32:1976;121-128.
56. Jahrling P.B., Scherer W.F. Histopathology and distribution of viral antigens in hamsters infected with virulent and benign Venezuelan encephalitis viruses. Am. J. Pathol. 72:1973a;25-38.
57. Jahrling P.B., Scherer W.F. Growth curves and clearance rates of virulent and benign Venezuelan encephalitis viruses in hamsters. Infect. Immun. 8:1973b;456-462.
58. Jahrling P.B., Stephenson E.H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J. Clin. Microbiol. 19:1984;429-431.
59. Kende M. Prophylactic and therapeutic efficacy of poly(I, C)-LC against Rift Valley fever virus infections in mice. J. Biol. Resp. Modif. 4:1985;503-511.
60. Kende M., Lupton H.W., Rill W.L., Gibbs P., Levy H.B., Canonico P.G. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infections in mice by incremental relative risk of death. Antimicrob. Agents Chemother. 31:1987;1194-1198.
61. Kim G.R., McKee K.T. Jr. Pathogenesis of Hantaan virus infection in suckling mice: clinical, virologic, and serologic observations. Am. J. Trop. Med. Hyg. 34:1985;388-395.
62. Kim Y.S., Ahn C., Han J.S., Kim S., Lee J.S., Lee P.W. Hemorrhagic fever with renal syndrome caused by the Seoul virus. Nephron. 71:1995;419-427.
63. Kinney R.M., Tsuchiya K.R., Sneider J.M., Trent D.M. Molecular evidence for the origin of the widespread Venezuelan equine encephalitis epizootic of 1969 to 1972. J. Gen. Virol. 73:1992;3301-3305.
64. Klingstrom J., Plyusnin A., Vaheri A., Lundkvist A. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J. Virol. 76:2002;444-449.
65. LeDuc J.W. Epidemiology of Hantaan and related viruses. Lab. Anim. Sci. 37:1987;413-418.
66. Lee H.W., Baek L.J., Johnson K.M. Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats. J. Infect. Dis. 146:1982;638-644.
67. Leon C.A. Sequelae of Venezuelan equine encephalitis in humans: a 4 year follow-up. Int. J. Epidemiol. 4:1975;131-140.
68. Liu C., Voth D.W., Rodina P., Shauf L.R., Gonzalez G. A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. J. Infect. Dis. 122:1970;53-63.
69. Lukaszewski R.A., Brooks R.J. Pegylated α-interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Virol. 74:2000;5006-5015.
70. McClain D.J., Summers P.L., Pratt W.D., Davis K.J., Jennings G.B. Experimental infection of nonhuman primates with sandfly fever virus. Am. J. Trop. Med. Hyg. 56:1997;554-560.
71. Mead J.R., Burger R.A., Yonk L.J., Coombs J., Warren R.P., Kende M., Huggins J., Sidwell R.W. Effect of human, recombinant interleukin-2 on Punta Toro virus infections in C57BL/6 mice. Antiviral Res. 15:1991;331-340.
72. Meadors G.F. III, Gibbs P.H., Peters C.J. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine. 4:1986;179-184.
73. Medovy H. Western equine encephalomyelitis in infants. J. Pediatr. 22:1943;308-318.
74. Meegan J.M. The Rift Valley fever epizootic in Egypt 1977-1978. 1. Description of the epizootic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 73:1979;618-623.
75. Meegan J.M., Shope R. Emerging concepts on Rift Valley fever. Perspect. Virol. 11:1981;267-287.
76. Meegan J.M., Watten R., Laughlin L. Clinical experience with Rift Valley fever in humans during the 1977 Egyptian epizootic. Conf. Epidemiol. Biostat. 3:1981;114-123.
77. Monath T.P., Calisher C.H., Davis M., Bowen G.S., White J. Experimental studies of rhesus monkeys infected with epizootic and enzootic subtypes of Venezuelan equine encephalitis virus. J. Infect. Dis. 129:1974;194-200.
78. Monath T.P., Kemp G.E., Cropp C.B., Chandler F.W. Necrotizing myocarditis in mice infected with western equine encephalitis virus: clinical, electrocardiographic, and histopathologic correlations. J. Infect. Dis. 138:1978;59-66.
79. Monroe M.C., Morzunov S.P., Johnson A.M., Bowen M.D., Artsob H., Yates T., Peters C.J., Rollin P.E., Ksiazek T.G., Nichol S.T. Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America. Emerg. Infect. Dis. 5:1999;75-86.
80. Morahan P.S., Pinto A., Stewart D., Murasko D.M., Brinton M.A. Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection. Antiviral Res. 15:1991;241-254.
81. Morgan I. Influence of age on susceptibility and on immune response of mice to eastern equine encephalomyelitis virus. J. Exp. Med. 74:1941;115-132.
82. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., Peters C.J. Prevention of Rift Valley fever in rhesus monkeys with interferon-α Rev. Infect. Dis. 11(Suppl. 4):1989;5815-5825.
83. Morris, C. 1988. Eastern equine encephalitis. In: Monath, T. (Ed.), The Arboviruses: Epidemiology and Ecology. CRC Press, Boca Raton, pp. 2-20.
84. Murphy F.A., Whitfield S.G. Eastern equine encephalitis virus infection: electron microscopic studies of mouse central nervous system. Exp. Mol. Pathol. 13:1970;131-146.
85. Murphy M.E., Kariwa H., Mizutani T., Yoshimatsu K., Arikawa J., Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol. 145:2000;1571-1582.
86. Mussgay M., Enzmann P.J., Horzinek M.C., Weiland E. Growth cycle of arboviruses in vertebrate and arthropod cells. Prog. Med. Virol. 19:1975;257-323.
87. Nichol, S. 2001. Bunyaviruses. In: Knipe, D., et al. (Eds.), Fields Virology. Lippincott Williams and Wilkins, Philadelphia, pp. 1603-1633.
88. Niklasson B., LeDuc J.W. Epidemiology of nephropathia epidemica in Sweden. J. Infect. Dis. 155:1987;269-276.
89. Oldfield E.C. III, Wallace M.R., Hyams K.C., Yousif A.A., Lewis D.E., Bourgeois A.L. Endemic infectious diseases of the Middle East. Rev. Infect. Dis. 13(Suppl. 3):1991;S199-S217.
90. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 6:1986;285-297.
91. Pifat D.Y., Smith J.F. Punta Toro virus infection of C57BL/6j mice: a model for phlebovirus-induced disease. Microb. Pathog. 3:1987;409-422.
92. Pinto A.J., Morahan P.S., Brinton M.A. Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses. Int. J. Immunopharmacol. 10:1988;197-209.
93. Pinto A.J., Morahan P.S., Brinton M., Stewart D., Gavin E. Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J. Interferon Res. 10:1990;293-298.
94. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 14:1996;337-343.
95. Randall R., Mills J., Engel L. The preparation and properties of a purified equine encephalomyelitis vaccine. J. Immunol. 55:1947;41-52.
96. Randall R., Binn L., Harrison V. Immunization against Rift Valley fever virus studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J. Immunol. 93:1964;293-299.
97. Richmond, J.Y., McKinney, R.W., 1999. Biosafety in Microbiological and Biomedical Laboratories. US Government Printing Office, Washington, pp. 1-250.
98. Sabin A., Philip C., Paul J. Phlebotomus (pappataci or sandfly) fever: a disease of military importance. Summary of existing knowledge and preliminary report of original investigations. J. Am. Med. Assoc. 125:1944;603-606.
99. Shepherd A.J., Swanepoel R., Leman P.A. Antibody response in Crimean/Congo hemorrhagic fever. Rev. Infect. Dis. 11(Suppl. 4):1989;S801-S806.
100. Siam A.L., Meegan J.M., Gharbawi K.F. Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt. Br. J. Ophthalmol. 64:1980;366-374.
101. Sidwell R.W., Gebhardt L.P., Thorpe B.D. Epidemological aspects of Venezuelan equine encephalitis virus infections. Bacteriol. Rev. 31:1967;65-81.
102. Sidwell R.W., Huffman J.H., Barnett B.B., Pifat D.Y. In vitro and in vivo phlebovirus inhibition by ribavirin. Antimicrob. Agents Chemother. 32:1988a;331-336.
103. Sidwell R.W., Huffman J.H., Barnard D.L., Pifat D.Y. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced phlebovirus infections. Antiviral Res. 10:1988b;193-208.
104. Sidwell R.W., Huffman J.H., Coombs J., Renis H., Huggins J., Kende M. A comparison of pyrimidinone analogue immunomodulators for treatment of phlebovirus infections in mice. Antivir. Chem. Chemother. 1:1990;241-247.
105. Sidwell R.W., Huffman J.H., Smee D.F., Gilbert J., Gessaman A., Pease A., Warren R.P., Huggins J., Kende M. Potential role of immunomodulators for treatment of phlebovirus infections of animals. NY Acad. Sci. 653:1992;344-355.
106. Sidwell R.W., Huffman J.H., Barnard D.L., Smee D.F., Warren R.P., Chirigos M.A., Kende M., Huggins J. Antiviral and immunomodulating inhibitors of experimentally induced Punta Toro virus infections. Antiviral Res. 25:1994;105-122.
107. Sidwell R.W., Huffman J.H., Barnard D.L., Smee D.F., Warren R.P., Kende M., Huggins J.W. Murine Punta Toro virus infection: a potential model for study of hantavirus inhibitors. Int. Antivir. News. 3:1995;34-36.
108. Skulnick H.I., Weed S.D., Eidson E.E., Renis H.E., Wierenga W., Stringfellow D.A. Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents. J. Med. Chem. 28:1985;1864-1869.
109. Smadel J. Epidemic hemorrhagic fever. Am. J. Publ. Health. 43:1951;1327-1330.
110. Smee D.F., Alaghamandan H.A., Kini G.D., Robins R.K. Antiviral activity and mode of action of ribavirin 5′-sulfamate against Semliki Forest virus. Antiviral Res. 10:1988;253-262.
111. Smee D.F., Huffman J.H., Hall L.L., Huggins J.W., Sidwell R.W. Inhibition of phlebovirus infections in vivo by tiazofurin and selenazofurin. Antivir. Chem. Chemother. 1:1990a;211-216.
112. Smee D.F., Alaghamandan H.A., Cottam H.B., Jolley W.B., Robins R.K. Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine. J. Biol. Resp. Mod. 9:1990b;24-32.
113. Smee D.F., Huffman J.H., Gessaman A.C., Huggins J.W., Sidwell R.W. Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice. Antiviral Res. 15:1991a;229-239.
114. Smee D.F., Alaghamandan H.A., Huffman J.H., Coombs J., Huggins J.W., Sidwell R.W. Combination chemotherapy of Punta Toro virus infections in mice using ribavirin and 7-thia-8-oxoguanosine. Antivir. Chem. Chemother. 2:1991b;93-97.
115. Smee D.F., Alaghamandan H.A., Gilbert J., Burger R.A., Jin A., Sharma B.S., Ramasamy K., Revankar G.R., Cottam H.B., Jolley W.B., Robins R.K. Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice. Antimicrob. Agents Chemother. 35:1991c;152-157.
116. Smee D.F., Alaghamandan H.A., Ramasamy K., Revankar G.R. Broad-spectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats. Antiviral Res. 26:1995;203-209.
117. Smithburn K., Haddow A. Semliki Forest virus. I. Isolation and pathogenic properties. J. Immunol. 49:1944;141-173.
118. Smithburn K., Mahaffy A., Haddow A. Rift Valley fever: accidental infections among laboratory workers. J. Immunol. 62:1949;213-227.
119. Steele K.E., Davis K.J., Stephan K., Kell W., Vogel P., Hart M.K. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HEN and BALB/c mice. Vet. Pathol. 35:1998;386-397.
120. Stephen, E., Jones, D., Peters, C.J., Eddy, G., Loizeaux, P., Jahrling, P., 1980. Ribavirin treatment of Toga-, Arena-, and Bunyavirus infections in subhuman primates and other laboratory animal species. In: Smith, R., Kirkpatrick, W. (Eds.), Ribavirin: A Broad Spectrum Antiviral Agent. Academic Press, New York, pp. 169-184.
121. Suleiman M.N., Muscat-Baron J.M., Harries J.R., Satti A.G., Platt G.S., Bowen E.T., Simpson D.I. Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid hospital. Lancet. 2:1980;939-941.
122. Swanepoel R., Gill D.E., Shepherd A.J., Leman P.A., Mynhardt J.H., Harvey S. The clinical pathology of Crimean/Congo hemorrhagic fever. Rev. Infect. Dis. 11(Suppl. 4):1989;S794-S800.
123. Tignor G.H., Hanham C.A. Ribavirin efficacy in an in vivo model of Crimean/Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res. 22:1993;309-325.
124. Vasilenko S., Levy S., Radev M. Investigations on the effectivity of killed vaccine against Crimean hemorrhagic fever (Bulgarian). Probl. Zaraz. Parazit. Bol. 3:1975;181-189.
125. Victor J., Smith D., Pollack A. The comparative pathology of Venezuelan equine encephalomyelitis. J. Infect. Dis. 98:1956;55-66.
126. Watts D.M., Ussery M.A., Nash D., Peters C.J. Inhibition of Crimean/Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am. J. Trop. Med. Hyg. 41:1989;581-585.
127. Weaver S.C., Salas R., Rico-Hesse R., Ludwig G.V., Oberste M.S., Boshell J., Tesh R.B. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet. 348:1996;436-440.
128. Wyckoff R., Tesar W. Equine encephalomyelitis in monkeys. J. Immunol. 37:1939;329-343.
129. Yoshimatsu K., Arikawa J., Ohbora S., Itakura C. Hantavirus infection in SCID mice. J. Vet. Med. Sci. 59:1997;863-868.
130. Zeller H., Bouloy M. Infections by viruses of the families Bunyaviridae and Filoviridae. Rev. Sci. Technol. 19:2000;79-91.
131. Zilinskas R.A. Iraq's biological weapons: the past as future? J. Am. Med. Assoc. 278:1997;418-424.
132. Zlotnick I., Harris W.J. The changes in cell organelles of neurons in the brains of adult mice and hamsters during Semliki Forest virus and Louping ill encephalitis. Br. J. Exp. Pathol. 51:1970;37-42.
133. Zlotnick I., Peacock S., Grant D.P. The pathogenesis of western equine encephalitis virus in adult hamsters with special reference to the long and short term effects on the CNS of the attenuated clone 15 variant. Br. J. Exp. Pathol. 53:1972;59-77.